MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2023 International Congress

    A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease

    E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To establish a minimal clinically important difference (MCID) for the Unified Huntington Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as a measure…
  • 2023 International Congress

    Metoclopramide-induced acute dystonic reaction caused by CYP2D6 *4/*4 and CYP2D6 *10/*10 genotypes

    I. šarac, H. šarac, F. Borovečki, N. Božina, I. Ivek, L. Bagarić Krakan, Z. Krešić (Zagreb, Croatia)

    Objective: Objective is to demonstrated the role of CYP P450 2D6 polymorphisms in metoclopramide-induced acute dystonic reactions. Background: Metoclopramide can induce acute extrapyramidal reactions by…
  • 2023 International Congress

    Deep brain stimulation in chorea: four cases and literature review

    M. Hull, M. Parnes, A. Tarakad (Houston, USA)

    Objective: We present four cases of pediatric chorea managed with deep brain stimulation (DBS) and review previously reported cases in the literature. We review clinical…
  • 2023 International Congress

    Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease

    R. Mehanna, E. Furr Stimming, D. Haubenberger, O. Klepitskaya, S. Aggarwal, S. Kumar, O. Topaloglu, J. Goldstein, E. Kayson, M. Serbin (Houston, USA)

    Objective: To conduct an indirect treatment comparison (ITC) between valbenazine and deutetrabenazine using data from clinical trials in adults with chorea associated with Huntington disease…
  • 2023 International Congress

    Modifying clinical and electrophysiological parameters through Transcranial pulsed current stimulation (tPCS) in Huntington disease

    M. Tuesta Bernaola, J. Ganguly, A. Parra Peña, M. Jog (London, Canada)

    Objective: 1. To assess brain network dysfunction of Huntington disease (HD). 2. To evaluate the effectiveness of 2-week home-based chronic non-invasive transcranial brain stimulation to…
  • 2023 International Congress

    Hazard ratios of suicidality in a large Huntington disease population compared with controls: marginal structural modeling of Enroll-HD registry data

    S. Reshef, V. Sung, G. Smith, O. Harari, D. Zhang, M. Forrest Gordon, R. Willock, R. Ribalov, J. Robles-Zurita, E. Furr Stimming (Parsippany-Troy Hills, USA)

    Objective: The aim of this study was to describe the risk of suicidality among individuals with versus those without Huntington disease (HD) from Enroll-HD. Background:…
  • 2023 International Congress

    Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model

    R. Wells, A. Azzam, A. Hiller, M. Sardinia (Portland, USA)

    Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…
  • 2023 International Congress

    Telemedicine and in-person encounters in a Huntington’s disease cohort: virtually the same

    E. Girouard, JF. Daneault, A. James-Palmer, S. Chouinard, A. Richard (Montréal, Canada)

    Objective: The aim of this study was to assess the impact of virtual care provision modalities (VPM) on patient satisfaction (PS) metrics for the specialized…
  • 2023 International Congress

    Emerging treatments targeting DNA and RNA in Huntington’s disease: a review of future perspectives and current challenges

    G. Lima, F. Sarmento, I. Camargo, R. Saba, S. Silva, V. Borges, H. Ferraz (São Paulo, Brazil)

    Objective: To review the progress made towards the development of a huntingtin (HTT) lowering strategy based on RNA and DNA and also to assess the…
  • 2023 International Congress

    A case of trichotillomania as the preceding symptom of Huntington’ s diseaseand the effect of risperidone

    Y. Degirmenci, N. Bicak (Istanbul, Turkey)

    Objective: Huntington's disease (HD) is a rare neurodegenerative disorder inherited by an autosomal dominant fashion which is most commonly characterised by choreic movement disorders. However,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley